This article is more than 5 years old. Information may no longer be current.

NICE final appraisal recommends funding Iluvien for pseudophakic DME patients

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The United Kingdom’s National Institute for Health and Care Excellence, or NICE, has issued a final appraisal determination calling for funding of Iluvien for the treatment of pseudophakic eyes in patients with chronic diabetic macular edema considered insufficiently responsive to available therapies, according to a news release.

The determination takes into account Alimera Sciences’ patient access scheme, which a NICE appraisal committee found in June met the necessary cost-effectiveness threshold. The final appraisal reverses NICE’s guidance from January.

The U.K., Austria, France, Portugal, Spain and Germany have granted national licenses for Iluvien (sustained-release fluocinolone acetonide intravitreal implant) after Alimera successfully completed the Decentralized Procedure. Marketing approval is pending in Italy, the release said.

The treatment has not been approved by the U.S. Food and Drug Administration.